-
Mashup Score: 6
“Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood” on Thursday, March 13, 2025 at 7:00 PM – 8:00 PM ET Please contact meetings@peerview.com with any questions regarding this program.
Source: us02web.zoom.usCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 8Living with spinal muscular atrophy while working in critical care - 9 month(s) ago
Jeremy Orr & Atul Malhotra interview Linsey Wehner
Source: www.thelancet.comCategories: General Medicine News, PulmonologyTweet-
NEW SPOTLIGHT - PATIENT PERSPECTIVES Living with spinal muscular atrophy while working in critical care #SMA "Patients are people first...Take the time to get to know them, to find out what motivates them, and to understand what gives them purpose" https://t.co/exnOfdVDj4 https://t.co/E7a1wBGU9Q
-
-
Mashup Score: 2Optimizing Outcomes in Adults With Spinal Muscular Atrophy: The Role of the Multidisciplinary Team - 2 year(s) ago
Did you know that even adults with less severe phenotypes of spinal muscular atrophy (SMA) lose an estimated 10 meters per year in their 6-minute walking distance test?
Source: www.medscape.orgCategories: Latest Headlines, PediatricsTweet-
❗ Did you know that even adults with less severe phenotypes of spinal muscular atrophy lose an estimated 10 meters per year in their 6-minute walking distance test? #SMA #MedEd #MedX #pediatrician 📝 https://t.co/80frHxqN1u https://t.co/DATQrAXE8a
-
-
Mashup Score: 1Optimizing Outcomes in Adults With Spinal Muscular Atrophy: The Role of the Multidisciplinary Team - 2 year(s) ago
Did you know that even adults with less severe phenotypes of spinal muscular atrophy (SMA) lose an estimated 10 meters per year in their 6-minute walking distance test?
Source: www.medscape.orgCategories: Latest Headlines, PediatricsTweet-
❗ Did you know that even adults with less severe phenotypes of spinal muscular atrophy lose an estimated 10 meters per year in their 6-minute walking distance test? #SMA #MedEd #MedX #pediatrician 📝 https://t.co/0Qnggd8oF8 https://t.co/OSlhjBCb9o
-
-
Mashup Score: 1SMA Gene Therapy Continues to Show Efficacy - 2 year(s) ago
Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for SMA.
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for spinal muscular atrophy #SMA @SMA_UK_ https://t.co/T7qSPC26Mi
-
-
Mashup Score: 0The Importance of Diagnosing SMA Early - 2 year(s) ago
Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses the importance of early diagnosis of spinal muscular atrophy (SMA).
Source: CheckRare.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses the importance of early spinal muscular atrophy #SMA diagnosis #checkrare #rarediseases @SMA_UK_ https://t.co/OS6miI4WZT
-
-
Mashup Score: 0Optimizing Outcomes in Adults With Spinal Muscular Atrophy: The Role of the Multidisciplinary Team - 2 year(s) ago
Did you know that even adults with less severe phenotypes of spinal muscular atrophy (SMA) lose an estimated 10 meters per year in their 6-minute walking distance test?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Did you know that even adults with less severe phenotypes of spinal muscular atrophy lose an estimated 10 meters per year in their 6-minute walking distance test? #SMA #MedEd #MedTwitter #pediatrician 📝 https://t.co/uyhCQM3hDZ https://t.co/zPYV4wtjbg
-
-
Mashup Score: 0SMA Gene Therapy Continues to Show Efficacy - 2 year(s) ago
Dr. Sitra Tauscher-Wisniewski, from Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for SMA.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sitra Tauscher-Wisniewski, MD, Vice President of Clinical Development & Analytics at Novartis Gene Therapies, discusses long-term data for onasemnogene abeparvovec (Zolgensma), an FDA-approved gene therapy for spinal muscular atrophy #SMA @SMA_UK_ https://t.co/T7qSPC26Mi
-
-
Mashup Score: 0Optimizing Outcomes in Adults With Spinal Muscular Atrophy: The Role of the Multidisciplinary Team - 2 year(s) ago
Did you know that even adults with less severe phenotypes of spinal muscular atrophy (SMA) lose an estimated 10 meters per year in their 6-minute walking distance test?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Did you know that even adults with less severe phenotypes of spinal muscular atrophy lose an estimated 10 meters per year in their 6-minute walking distance test? #SMA #MedEd #MedTwitter #pediatrician 📝 https://t.co/BZvrbv479P https://t.co/1J6Um7tWhp
-
-
Mashup Score: 0Optimizing Outcomes in Adults With Spinal Muscular Atrophy: The Role of the Multidisciplinary Team - 2 year(s) ago
Did you know that even adults with less severe phenotypes of spinal muscular atrophy (SMA) lose an estimated 10 meters per year in their 6-minute walking distance test?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
❗ Did you know that even adults with less severe phenotypes of spinal muscular atrophy lose an estimated 10 meters per year in their 6-minute walking distance test? #SMA #MedEd #MedTwitter #pediatrician 📝 https://t.co/8bzF8p7DPf https://t.co/N8fnZFOV1M
-
🧠 Excited to collaborate with @PeerView on this important #SMA program! Learn from experts like Dr. Claudia A. Chiriboga about ensuring comprehensive care as patients transition to adulthood. 3/13 Register now: https://t.co/cmDfm0nkgr https://t.co/6DCPRvZkPn